4.7 Article

A Novel Aldisine Derivative Exhibits Potential Antitumor Effects by Targeting JAK/STAT3 Signaling

Journal

MARINE DRUGS
Volume 21, Issue 4, Pages -

Publisher

MDPI
DOI: 10.3390/md21040218

Keywords

JAK; STAT3 signaling pathway; aldisine derivatives; isothiouronium; antitumor activity; JAK inhibitor; high-throughput screening

Ask authors/readers for more resources

The JAK/STAT3 signaling pathway is hyperactivated in many cancers, and inhibitors targeting this pathway have great potential for cancer treatment. In this study, we modified aldisine derivatives by introducing the isothiouronium group, which improved their antitumor activity. Through high-throughput screening, we identified compound 11c as a potent inhibitor of JAK/STAT3 activities. Further experiments showed that compound 11c effectively inhibited STAT3 activation and induced apoptosis in cancer cells. In an in vivo tumor xenograft experiment, compound 11c demonstrated significant antitumor effects.
The JAK/STAT3 signaling pathway is aberrantly hyperactivated in many cancers, promoting cell proliferation, survival, invasiveness, and metastasis. Thus, inhibitors targeting JAK/STAT3 have enormous potential for cancer treatment. Herein, we modified aldisine derivatives by introducing the isothiouronium group, which can improve the antitumor activity of the compounds. We performed a high-throughput screen of 3157 compounds and identified compounds 11a, 11b, and 11c, which contain a pyrrole [2,3-c] azepine structure linked to an isothiouronium group through different lengths of carbon alkyl chains and significantly inhibited JAK/STAT3 activities. Further results showed that compound 11c exhibited the optimal antiproliferative activity and was a pan-JAKs inhibitor capable of inhibiting constitutive and IL-6-induced STAT3 activation. In addition, compound 11c influenced STAT3 downstream gene expression (Bcl-xl, C-Myc, and Cyclin D1) and induced the apoptosis of A549 and DU145 cells in a dose-dependent manner. The antitumor effects of 11c were further demonstrated in an in vivo subcutaneous tumor xenograft experiment with DU145 cells. Taken together, we designed and synthesized a novel small molecule JAKs inhibitor targeting the JAK/STAT3 signaling pathway, which has predicted therapeutic potential for JAK/STAT3 overactivated cancer treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available